Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ziyad Ayyoub

Physical Medicine & Rehabilitation Paramount, CA Medical Doctor

NPI 1356451579 CMS profile 106399

16660 Paramount Blvd Ste 101, Paramount, CA 90723

Open in the dashboard

General payments

$321,630

425 records reported · program years 2019–2025

Research payments

$1,496

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,430,427 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Ziyad Ayyoub of Paramount, CA is reported in the CMS Open Payments database as having received $321,630 across 425 general payments and $1,496 in research payments paid to them. Separately, studies naming them as principal investigator received $1,430,427 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $22,399 22
2024 General $37,561 65
2024 Research $1,496 3
2023 General $47,457 68
2022 General $47,016 48
2021 General $62,466 47
2020 General $28,366 34
2019 General $76,365 141

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ziyad Ayyoub
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Ziyad Ayyoub were reported at $22,399. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Ziyad Ayyoub Physical Medicine & Rehabilitation median Middle half National median
2019 $76,365 $133 $45–$390 $163
2020 $28,366 $88 $29–$272 $114
2021 $62,466 $116 $33–$360 $132
2022 $47,016 $123 $40–$378 $149
2023 $47,457 $131 $43–$396 $160
2024 $37,561 $141 $45–$409 $164
2025 $22,399 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $92,784 105 payments
  2. Allergan Inc. $92,173 89 payments
  3. Ipsen Biopharmaceuticals, Inc $68,504 59 payments
  4. Merz North America, Inc. $30,244 42 payments
  5. US WorldMeds, LLC $16,795 52 payments
  6. Merz Pharmaceuticals, LLC $5,754 34 payments
  7. Ipsen Innovation $5,735 5 payments
  8. Ipsen Biopharm Limited $4,380 1 payment
  9. Pacira Pharmaceuticals Incorporated $2,183 16 payments
  10. Ipsen Pharma SAS $1,914 5 payments
  11. Other $1,165 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $210,030 70 payments
  2. Consulting Fee $47,459 29 payments
  3. Honoraria $29,795 13 payments
  4. Travel and Lodging $20,232 72 payments
  5. Food and Beverage $13,943 238 payments
  6. Education $172 3 payments
Products named General payments · program years 2019–2025
  1. BOTOX Neuroscience $139,531 97 payments
  2. DYSPORT $80,404 69 payments
  3. Xeomin $35,305 64 payments
  4. BOTOX Neuroscience $25,335 25 payments
  5. BOTOX Botox Therapeutic $15,470 40 payments
  6. MYOBLOC $15,415 50 payments
  7. APOKYN $6,310 18 payments
  8. Xadago $6,310 18 payments
  9. BOTOX Facial Aesthetics $2,038 4 payments
  10. Zilretta $1,175 8 payments
  11. Other $4,136 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Merz Pharmaceuticals, LLC $1,496 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

336

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$184,491

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

69%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Botox Onabotulinumtoxina Brand 73 $181,411
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 123 $1,362
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 36 $798
Gabapentin Generic 50 $445
Oxycodone Hcl Generic 13 $352
Ibuprofen Generic 22 $68
Baclofen Generic 19 $56

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$483,015

Medicare's payments for the services billed

Medicare patients

362

Average age 72

Services billed

6,941

192 women, 170 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Heart failure 72%
Chronic kidney disease 68%
Depression 57%
Arthritis 57%
Ischemic heart disease 54%
COPD 49%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $29,036
$29,036 73 —
DYSPORT
  • Ipsen Biopharmaceuticals, Inc $6,509
$6,509 — —
Zilretta
  • Pacira Pharmaceuticals Incorporated $1,175
$1,175 — —
Xeomin
  • Merz Pharmaceuticals, LLC $420
$420 — —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $125
$125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

428 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record